and Christy, you, everyone. Thank hello,
dive our where like I’d an year. protocol we a this on we June First, status in RAISE announced with into provide deeper stand bit amendment epilepticus update IV the in and programs to
trial of inclusion agents X transferred other of IV patients such IV than common up excluding treated with represented an We brief anesthetics been high because the shared, of believe the from any significant hospitals Two these identification randomization emergency rather of As ICU will the hours epilepticus. we’ve been of patient the excluded the been. most who The who’ve who dose important XX previously anesthetics permit to for room. to we original to enrollment this status how high of criteria doses proportion is refractory broaden these protocol propofol or treated pathways as of with the the allow it for Phase regardless administration of may for many patients patients had change or population. the have
it’s also to criteria think patients would of prior enrolled under that revised to I important the protocol. the the eligibility meet amendment still implementation mention
to the amendment year As Scott potential protocol Investigators the protocol remaining the number mentioned, patients. to of to the changes end. RAISE a sites sites protocol with enthusiasm have in revised the greater considerable recruitment of implemented about the expected the have majority of transition by allow of expressed eligible
the reviewed all held we Phase we will in Canada expand trial them We and the to expect investigator timely U.S. which we recently protocol. work our in In meetings amended updated continue in on under baseline study plan patients. closely be protocol RAISE the the centers number sites to continue study and RAISE to support educate to participating to the August characteristics We sites the of with enrollment. X November, Australia, of and U.S. activated the the expand and of
outlined history similar and the X September, our both patients a lean A proportion age. closely and share our epilepticus studies enrolled on same have are burdens study. patients characteristics status they These severity. in baseline are of deck. the similar XX RSE the of as the have November Phase roughly baseline seizure epilepsy demographics pleased that We’re Phase of corporate to X resemble Slide of Participants those of in
study data Phase there ongoing on and the RSE X an a no in September, that condition RAISE epilepticus. rigorously on trial for of researchers trial addition, field. presentation advance presented conducted In a The status the clinicians which They the those response Colloquium in express leading are overview was we placebo-controlled from research at status, RAISE the who from the an in attendance studies. data positive and clinical refractory represents London-Innsbruck received from
Neurocritical We we with had had many the presentation. attend program, Society the investigators a as presented from ganaxolone two sites. IV poster posters There, designated distinguished study one data Marinus RAISE the several and October was meet Annual from members also other of to Meeting which in representatives Care we opportunity with where team
in interest in expressed neurocritical centers the trial. participating Additionally, from physicians care other leading
future Looking patients for trial over. of execution. years can patients. will at There's study, the to support and the also monitor and potential of site to trial enroll we and we expansion what's can working well provide where ages actively a eligible the Currently, continue for the RAISE range XX age level the of additional recruitment
submitting supporting us potentially We will the shortly be include patients. a to data to that with allowed younger request FDA
the epilepticus further children incidence the Given of under and support in patients of pool study this higher XX, expand status enrollment. timely change eligible could
the committee or XX previously stopping have interim is if time, committee full study, an independent monitoring enrollment. conducted, participants approximately the option would the that to analysis disclosed, have to efficacy interim of completed At when study As two-thirds for conduct we the continuing an recommend the either for patients. data
a a conduct be to treatment may continue analysis effect to While an of the study affect enrollment. should sensitivity of full interim detect
data ganaxolone second not of We're a only approval We trial. fully effect the to is have the and half to designed we X a of the European Planning This study RAISE half strategy. study application critical XXXX. the interim XXXX. have begin finalized enrollment to of second analysis X believe is U.S. the the indication pleased to have in trial Europe. potential it outcome serve on the efficacy IV and protocol top support to expected minimal the a line of expect further trial Phase as The has with a piece a the broaden enrollment the RSC to changes RAISE the the for of in enrolled for support separate in continue marketing also trial, We will continues for RAISE made in authorization
Moving X in study on epilepticus. Phase to the status RESET established
begin additional to advance year expect and site first the to the activated have from this We and continue enrollment sites. consent exception informed process U.S. we for
Now, I'd to turn oral programs. like to our ganaxolone
X community. of continued awareness extension a open-label the Phase data we our meeting to from and increase As October study, Christy over On the including that continue medical stated scientific Neurology at in to her two-year pivotal two posters ZTALMY XX, work across Marigold seizure reduction presented remarks, Society period. Child we showed
double-blind The of was XX% the of with suggest data but phase. may reductions on XX XX.X% XX% reduction XX in during the a major open-label for the continued to improve long-term remaining versus the remain only motor Although second. frequency. year during the demonstrate conclusion at phase, patients first seizure rate the data in about about the for XX was the month open-label frequency treatment extension, declined seizure mark median who continued reduction total discontinuation at month available the to of reduction XX% XX this These the patients of in a in subset
mood It hoc a the showed certain scale. was ZTALMY domains administered the analysis from reductions associated was anxiety, in with which and scale. of specifically study, compulsive manic Marigold depression, data the behavior presented improvements hyperactive and also We behavior, of in components from the during post
While require research, would these that may there seizure confirmation benefits findings of beyond be treatment through they reduction. potential suggest further
the XXXX. first data Moving complex, and are Israel community U.S. We're of sclerosis of that and half in to we year activations in the predominantly this tuberous quarter level X targeting the in XX line by TrustTSC of the encouraged clinical top screening Australia we patients. trial enthusiasm trial We're with and sites Canada end share actively in continue high to for the with are to our in Europe and medical expected in Phase anticipate pleased first XXXX.
to like second formulations. our generation I'd with update provide you an on Finally,
Phase efficacy formulation of As the milligrams reformulation given our study profile the of it a clinical in which potentially initial single to ranging in first with or study additional the for could X XXX the of further whether that increase concentration from reference relative this shared next titration Cmax. such overall we exposure oral peak in Participants showed the development. last a results Phase beyond received the oral current evolution ascending of effects doses promising optimize without quarter, we current suspension believe related of saw to Cmax as upward the oral allow ganaxolone support from Therefore, producing steps candidates, Sonance. dose in The to XXX in a the cohort this doses reformulated new XXX relative adverse dose to an exposure X above Phase we program study include PK further to single suspension concentration. as X overall milligrams enrollment maximum increases of to in determine assess achieve increases additional The concomitant advancing control. can
of data end We to by expect of the the XXXX. first the be quarter available
study half which for initiate XXXX. selecting to one of the in modeling will formulations formulation, steps ascending We of first has is the refractory multiple be believe to new which dosing exposure achieve each and allow in optimal X to Phase consistent Syndrome oral potential response we more individualize physicians would to to the we highly for begin the Lennox-Gastaut to patient. expect predictable be also with this generation ganaxolone next anticipate the PK performing position for doses, provide the development Syndrome and including need determine of treated to Lennox-Gastaut formulation a second a an in ganaxolone, we study in a XXXX. would We in
we'll sessions, additional targeted forward several in dose coming Epilepsy improvements selected developed well to annual months, individualization and of in oral XXXX. could We been and IV we've American Phase operational and and to efficacy, medical general raise manufacturing Society candidates presentations presence well of scientific within a pro-drug from as including further with during ganaxolone robust Scientific programs Exhibit. the meeting have Lead, X as Additionally, as pro-drug look for and continuing that oral and IND-enabling community December, over candidates awareness have the Marinus during the data efficiencies. studies data offer as our the for tolerability
As continued Complex, our ZTALMY and as on Epilepticus a reformulation candidates, our programs and focused for pro-drug and well support advancing Sclerosis clinical Phase CDD. clinical Status remain and we our as X Tuberous team,
Now, CFO, I'll over Pfanstiel, a financial will our who you provide to call turn Steve with the update.
